BRPI0816708A2 - Inibidor de proteína tau quinase à base de 3-metil-2-((2s)-2-(4-(3-metil-l,2,4-oxadiazol-5-il)fenil)mor folino)-6-(pirimidin-a)-(3h)-ona - Google Patents

Inibidor de proteína tau quinase à base de 3-metil-2-((2s)-2-(4-(3-metil-l,2,4-oxadiazol-5-il)fenil)mor folino)-6-(pirimidin-a)-(3h)-ona

Info

Publication number
BRPI0816708A2
BRPI0816708A2 BRPI0816708A BRPI0816708A2 BR PI0816708 A2 BRPI0816708 A2 BR PI0816708A2 BR PI0816708 A BRPI0816708 A BR PI0816708A BR PI0816708 A2 BRPI0816708 A2 BR PI0816708A2
Authority
BR
Brazil
Prior art keywords
methyl
oxadiazol
pyrimidin
morpholine
phenyl
Prior art date
Application number
Other languages
English (en)
Inventor
Daiki Sakai
Kazutoshi Watanabe
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0816708A2 publication Critical patent/BRPI0816708A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
BRPI0816708 2007-09-14 2008-09-12 Inibidor de proteína tau quinase à base de 3-metil-2-((2s)-2-(4-(3-metil-l,2,4-oxadiazol-5-il)fenil)mor folino)-6-(pirimidin-a)-(3h)-ona BRPI0816708A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007269484 2007-09-14
JP2007275714 2007-09-25
PCT/JP2008/066929 WO2009035159A1 (en) 2007-09-14 2008-09-12 3-methyl-2- ( (2s) -2- (4- (3-methyl-l, 2, 4-0xadiaz0l-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor

Publications (1)

Publication Number Publication Date
BRPI0816708A2 true BRPI0816708A2 (pt) 2015-03-17

Family

ID=40085496

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816708 BRPI0816708A2 (pt) 2007-09-14 2008-09-12 Inibidor de proteína tau quinase à base de 3-metil-2-((2s)-2-(4-(3-metil-l,2,4-oxadiazol-5-il)fenil)mor folino)-6-(pirimidin-a)-(3h)-ona

Country Status (14)

Country Link
US (1) US8288383B2 (pt)
EP (1) EP2197877B1 (pt)
JP (1) JP5449147B2 (pt)
KR (1) KR20100074183A (pt)
CN (1) CN101842371A (pt)
AR (1) AR068438A1 (pt)
AU (1) AU2008297814A1 (pt)
BR (1) BRPI0816708A2 (pt)
CA (1) CA2698818A1 (pt)
EA (1) EA201070366A1 (pt)
MX (1) MX2010002766A (pt)
TW (1) TW200927133A (pt)
WO (1) WO2009035159A1 (pt)
ZA (1) ZA201002214B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
AR064660A1 (es) 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
US8940738B2 (en) 2009-08-13 2015-01-27 Mitsubishi Tanabe Pharma Corporation Pyrimidone compounds
WO2012007426A1 (en) 2010-07-13 2012-01-19 Basf Se Azoline substituted isoxazoline benzamide compounds for combating animal pests
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9181230B2 (en) 2012-01-12 2015-11-10 Hoffmann-La Roche Inc. Morpholine compounds and uses thereof
NZ702571A (en) 2012-06-29 2017-02-24 Pfizer 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
CN113831296B (zh) * 2021-07-27 2023-07-21 北京理工大学 1-苯基-3-(4-(嘧啶-5-基氨基)苯基)丙-2-烯-1-酮类化合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037888A1 (en) * 2001-09-21 2003-05-08 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
AU2002337498B2 (en) * 2001-09-21 2006-08-10 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
KR20100074183A (ko) 2010-07-01
WO2009035159A1 (en) 2009-03-19
MX2010002766A (es) 2010-05-19
EP2197877A1 (en) 2010-06-23
CN101842371A (zh) 2010-09-22
ZA201002214B (en) 2011-06-29
US8288383B2 (en) 2012-10-16
JP2010538970A (ja) 2010-12-16
TW200927133A (en) 2009-07-01
EP2197877B1 (en) 2013-05-15
EA201070366A1 (ru) 2010-08-30
JP5449147B2 (ja) 2014-03-19
AU2008297814A1 (en) 2009-03-19
US20110003988A1 (en) 2011-01-06
AR068438A1 (es) 2009-11-18
CA2698818A1 (en) 2009-03-19
WO2009035159A8 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
BRPI0816708A2 (pt) Inibidor de proteína tau quinase à base de 3-metil-2-((2s)-2-(4-(3-metil-l,2,4-oxadiazol-5-il)fenil)mor folino)-6-(pirimidin-a)-(3h)-ona
CY2017038I2 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν 4-(4-(3-(4-χλωρο-3-τριφθορομεθυλ-φαινυλ)-ουρειδο)-3-φθορο-φαινοξυ)-πυριδιν-2-καρβοξυλικο οξυ για thν θεραπευτικη αγωγη υπερπολλαπλασιαστικων διαταραχων
CY2014029I1 (el) Ισοξαζολινες για τον ελεγχο ασπονδυλων παρασιτων
DK1954241T3 (da) Zonisamid-formulering med vedvarende frigivelse
DK3540062T3 (da) Immunoglobulin-variabel region kassetteudskiftning
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
NO20082514L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
ATE518446T1 (de) Arbeitstisch
DE602006003113D1 (de) Aiguille à ponction guidee ultrasoniquement
ATE442539T1 (de) Rollspindel
DE502005000984D1 (de) Taumelfingergetriebe
DE602005023936D1 (de) Kühlmittelzusammensetzung
DE602005011371D1 (de) Kühlgerät
DE602005011245D1 (de) Spiralmaschine
DK1861389T3 (da) 7-(2-(4-(3-triflourmethylphenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl)isoquinoleinbesylatsalt
ITMO20050254A1 (it) Gruppo abrasivo
DE502005007998D1 (de) Schleifkörperhalter
NO20070299L (no) Novel heterocyclic compounds
BRPI0815754A2 (pt) métodos para preparar compostos à base de 4-fenil-6-(2,2,2-trifluoro-1-feniletóxi)pirimidina
DE602006003075D1 (de) Uracilen und 3-sulfonylisoxazolinen
DK1863791T5 (da) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidiner som CGRP-antagonister
DE602005025774D1 (de) Halsringkühlung
FI6695U1 (fi) Termotela
DE602006001471D1 (de) Poliervorrichtung
DE502006006923D1 (de) Hochdrehende Arbeitsspindel

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.